We determined the effects of CC-96191 or lintuzumab on freshly collected bone marrow specimens from 10 patients with newly diagnosed (n = 8) or relapsed/refractory (n = 2) CD33+ AML. This evidence concerns the gene CD33 and acute myeloid leukemia.